Axonics Stock Price, News & Analysis (NASDAQ:AXNX)

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXNX shares.
View AXNX analyst ratings or view top-rated stocks.

10 brokerages have issued 1 year price targets for Axonics' stock. Their AXNX share price targets range from $63.00 to $75.00. On average, they predict the company's stock price to reach $71.60 in the next twelve months. This suggests a possible upside of 24.7% from the stock's current price.
View analysts price targets for AXNX or view top-rated stocks among Wall Street analysts.

Axonics' stock was trading at $62.53 at the beginning of 2023. Since then, AXNX shares have decreased by 8.1% and is now trading at $57.44.
View the best growth stocks for 2023 here.

Axonics saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 2,160,000 shares, a decline of 22.0% from the October 31st total of 2,770,000 shares. Based on an average trading volume of 557,600 shares, the short-interest ratio is currently 3.9 days.
View Axonics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our AXNX earnings forecast.

Axonics, Inc. (NASDAQ:AXNX) announced its earnings results on Monday, October, 30th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.13. The business earned $93.10 million during the quarter, compared to analysts' expectations of $89.60 million. Axonics had a negative trailing twelve-month return on equity of 2.04% and a negative net margin of 3.50%. The business's revenue for the quarter was up 32.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.34) EPS.

ETFs with the largest weight of Axonics (NASDAQ:AXNX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Fidelity Digital Health ETF (FDHT), SPDR S&P Health Care Equipment ETF (XHE), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Nuveen Small Cap Select ETF (NSCS), Principal Healthcare Innovators ETF (BTEC) and Goldman Sachs Future Health Care Equity ETF (GDOC).iShares U.S. Medical Devices ETF (IHI).

Axonics issued an update on its FY 2023 earnings guidance on Friday, September, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $358.00 million-$358.00 million, compared to the consensus revenue estimate of $358.73 million.

20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include RTX (RTX), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

(AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Axonics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (9.00%), Bamco Inc. NY (3.55%), Invesco Ltd. (3.23%), Loomis Sayles & Co. L P (2.47%), Mackenzie Financial Corp (2.46%) and Artisan Partners Limited Partnership (1.26%). Insiders that own company stock include Alfred J Ford Jr, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Raymond W Cohen, Raymond W Cohen, Rinda Sama and Robert E Mcnamara.
View institutional ownership trends.

Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.